| Bioactivity | HEMADO is a potent and selective adenosine A3 receptor agonist with a Ki of 1.1 nM at the human A3 subtype[1]. | |||||||||
| Target | Ki: 1.1 nM (human A3 subtype) | |||||||||
| Invitro | HEMADO (compound 8a) has Kis of 327 nM and 1230 nM for A1 and A2A and a EC50 of 100 μM for A2B receptors[2]. | |||||||||
| Name | HEMADO | |||||||||
| CAS | 403842-38-6 | |||||||||
| Formula | C17H23N5O4 | |||||||||
| Molar Mass | 361.40 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Klotz KN, et al. [3H]HEMADO— a novel tritiated agonist selective for the human adenosine A3 receptor. Eur J Pharmacol. 2007 Feb 5;556(1-3):14-8. Epub 2006 Oct 27. [2]. Volpini R, et al. N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9. |